Cooper Haims Advisors LLC purchased a new position in shares of Eli Lilly And Co (NYSE:LLY) during the 1st quarter, HoldingsChannel reports. The institutional investor purchased 21,561 shares of the company’s stock, valued at approximately $2,798,000. Eli Lilly And Co makes up approximately 0.9% of Cooper Haims Advisors LLC’s holdings, making the stock its 18th largest position.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Athena Capital Advisors LLC acquired a new position in Eli Lilly And Co during the 4th quarter valued at about $26,000. Wakefield Asset Management LLLP acquired a new position in Eli Lilly And Co during the 4th quarter valued at about $27,000. Larson Financial Group LLC acquired a new position in Eli Lilly And Co during the 4th quarter valued at about $29,000. Ironwood Financial llc acquired a new position in Eli Lilly And Co during the 4th quarter valued at about $30,000. Finally, Trust Department MB Financial Bank N A lifted its position in Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares during the period. Institutional investors and hedge funds own 79.17% of the company’s stock.
NYSE LLY opened at $116.22 on Friday. The company has a market capitalization of $112.42 billion, a PE ratio of 20.86, a P/E/G ratio of 2.05 and a beta of 0.27. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85. Eli Lilly And Co has a 12 month low of $80.96 and a 12 month high of $132.13.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating the consensus estimate of $1.32 by $0.01. The company had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.31 EPS. On average, sell-side analysts forecast that Eli Lilly And Co will post 5.66 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Friday, May 17th will be issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a yield of 2.22%. The ex-dividend date is Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio is 46.49%.
LLY has been the topic of a number of research reports. Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. UBS Group cut their target price on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research report on Friday, February 8th. Bank of America set a $129.00 target price on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Thursday, March 21st. Citigroup set a $124.00 target price on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Tuesday, February 26th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Eli Lilly And Co in a research report on Tuesday, March 12th. They set an “overweight” rating and a $140.00 target price on the stock. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $118.83.
In other Eli Lilly And Co news, SVP Enrique A. Conterno sold 25,000 shares of the firm’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $121.00, for a total transaction of $3,025,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Aarti S. Shah sold 1,800 shares of the firm’s stock in a transaction on Friday, April 5th. The shares were sold at an average price of $125.85, for a total value of $226,530.00. Following the sale, the senior vice president now directly owns 18,425 shares of the company’s stock, valued at approximately $2,318,786.25. The disclosure for this sale can be found here. Insiders have sold a total of 870,959 shares of company stock valued at $109,672,752 in the last ninety days. Insiders own 0.11% of the company’s stock.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: S&P 500 Index
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.